<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359956</url>
  </required_header>
  <id_info>
    <org_study_id>SICOG 0109</org_study_id>
    <nct_id>NCT01359956</nct_id>
  </id_info>
  <brief_title>Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma</brief_title>
  <acronym>SICOG 0109</acronym>
  <official_title>Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated two chemotherapy regimens with and without the addition of interferon in&#xD;
      patients with advanced or recurrent melanoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Overall Survival was defined as the time from the date of randomisation to the date of death from any cause or the date of last follow-up for living patients.&#xD;
OS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two - sided log - rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Progression Free Survival (PFS) was defined as the time from the date of randomisation to the date of progression of disease or death from any cause, whichever occurred first, or date of last follow-up for patients without progression and alive at the end of the study.&#xD;
PFS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two-sided log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>18 weeks from start of therapy</time_frame>
    <description>Overall Response Rate (ORR) included Complete Response (CR) and Partial Response (PR).&#xD;
Complete Response (CR) was defined as disappearance of all symptoms and signs of all measurable disease, lasting for at least four weeks, without appearance of new lesions.&#xD;
Partial Response (PR) was defined as a &gt; 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, lasting for at least four weeks, without appearance of new lesions or enlargement of existing lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Toxicity</measure>
    <time_frame>at end of each 3 week cycle of therapy up to the discontinuation</time_frame>
    <description>worst grade CTC toxicity, for each cycle and overall, will be reported for each treatment arm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination chemotherapy without interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination chemotherapy with interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single agent dacarbazine without interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single agent dacarbazine plus interferon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>900 mg / m2 every 3 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fotemustine</intervention_name>
    <description>100 mg / m2 every 3 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2b</intervention_name>
    <description>5 M units every 3 weeks</description>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of malignant melanoma in advanced stage or&#xD;
             recurrent after surgery, and not amenable to further surgery or local therapy.&#xD;
&#xD;
          -  Presence of measurable disease&#xD;
&#xD;
          -  Age &gt; or = 18 years and &lt; or = 75 years&#xD;
&#xD;
          -  Performance status (ECOG) 0 - 2 (Appendix 2)&#xD;
&#xD;
          -  Life expectancy ³ 3 months&#xD;
&#xD;
          -  Adequate bone marrow function (ANC ³ 2,000/mmc; PTL ³ 100,000/mmc; Hb ³ 10 gr/dl),&#xD;
             normal liver and renal function (bilirubin &lt; 1.25 x N, creatinine &lt; 1.25 x N, SGOT,&#xD;
             SGPT &lt; 3 times upper normal limit of testing laboratory.&#xD;
&#xD;
          -  Written, informed consent prior to study specific procedures, with the understanding&#xD;
             that the patient has the right to withdraw from the study at any time, without&#xD;
             prejudice.&#xD;
&#xD;
          -  Prior surgery &gt; 3 weeks from initiating .&#xD;
&#xD;
          -  If palliative radiation is needed, in case of non target lesions, it must be given&#xD;
             prior to initiating chemotherapy. If palliative radiation is required during the study&#xD;
             the patient should be permanently discontinued from further treatment.&#xD;
&#xD;
          -  Adequate contraceptive measures during study participation for sexually active&#xD;
             patients of child bearing potential must implement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent malignancies at other sites with the exception of surgically&#xD;
             cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the&#xD;
             skin.&#xD;
&#xD;
          -  Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed)&#xD;
&#xD;
          -  Known HIV disease.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs.&#xD;
&#xD;
          -  Concurrent chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and&#xD;
             replacement steroids), radiation therapy&#xD;
&#xD;
          -  Pregnant or lactating females Previous or concurrent malignancies at other sites with&#xD;
             the exception of surgically cured carcinoma in-site of the cervix and basal or&#xD;
             squamous cell carcinoma of the skin.&#xD;
&#xD;
        Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed) Known HIV disease.&#xD;
        Concurrent treatment with other experimental drugs. Concurrent chemotherapy, immunotherapy,&#xD;
        hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo A Ascierto, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Daponte, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simona Signoriello, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <results_reference>
    <citation>Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38.</citation>
    <PMID>23402397</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>October 18, 2020</last_update_submitted>
  <last_update_submitted_qc>October 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Fotemustine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomly assigned to one of four treatment groups. Patients were randomized through a computerized procedure of permuted blocks centralized at the coordinating center (Medical Oncology, NCI Napoli), stratified by PS (0-1,2) and site of metastases (visceral, not visceral).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>A1 - Combination Chemotherapy Without Interferon</title>
          <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
        </group>
        <group group_id="P2">
          <title>A2 - Combination Chemotherapy With Interferon</title>
          <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
        <group group_id="P3">
          <title>B1 - Single Agent Dacarbazine Without Interferon</title>
          <description>single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
        </group>
        <group group_id="P4">
          <title>B2 - Single Agent Dacarbazine Plus Interferon</title>
          <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Nine patients were lost to follow-up immediately after randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>A1 - Combination Chemotherapy Without Interferon</title>
          <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
        </group>
        <group group_id="B2">
          <title>A2 - Combination Chemotherapy With Interferon</title>
          <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
        <group group_id="B3">
          <title>B1 - Single Agent Dacarbazine Without Interferon</title>
          <description>single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
        </group>
        <group group_id="B4">
          <title>B2 - Single Agent Dacarbazine Plus Interferon</title>
          <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="58"/>
            <count group_id="B5" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="13"/>
                    <measurement group_id="B2" value="50" spread="15"/>
                    <measurement group_id="B3" value="59" spread="15"/>
                    <measurement group_id="B4" value="56" spread="14"/>
                    <measurement group_id="B5" value="55" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodular melanoma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall Survival was defined as the time from the date of randomisation to the date of death from any cause or the date of last follow-up for living patients.&#xD;
OS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two - sided log - rank test.</description>
        <time_frame>24 months</time_frame>
        <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D, 128 instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134 instead of 138 (4 lost pts.)</population>
        <group_list>
          <group group_id="O1">
            <title>Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine/Interferon + Dacarbazine</title>
            <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
          <group group_id="O3">
            <title>Fotemustine/Dacarbazine/Interferon+Dacarbazine/Interferon</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
          </group>
          <group group_id="O4">
            <title>Fotemustine/Dacarbazine + Dacarbazine</title>
            <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall Survival was defined as the time from the date of randomisation to the date of death from any cause or the date of last follow-up for living patients.&#xD;
OS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two - sided log - rank test.</description>
          <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D, 128 instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134 instead of 138 (4 lost pts.)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.6" upper_limit="10.2"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.3" upper_limit="10.4"/>
                    <measurement group_id="O3" value="9.1" lower_limit="6.3" upper_limit="11.1"/>
                    <measurement group_id="O4" value="7.7" lower_limit="6.3" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression Free Survival (PFS) was defined as the time from the date of randomisation to the date of progression of disease or death from any cause, whichever occurred first, or date of last follow-up for patients without progression and alive at the end of the study.&#xD;
PFS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two-sided log-rank test.</description>
        <time_frame>12 months</time_frame>
        <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D, 128 instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134 instead of 138 (4 lost pts.).</population>
        <group_list>
          <group group_id="O1">
            <title>Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine/Interferon + Dacarbazine</title>
            <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
          <group group_id="O3">
            <title>Fotemustine/Dacarbazine/Interferon+Dacarbazine/Interferon</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
          </group>
          <group group_id="O4">
            <title>Fotemustine/Dacarbazine + Dacarbazine</title>
            <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression Free Survival (PFS) was defined as the time from the date of randomisation to the date of progression of disease or death from any cause, whichever occurred first, or date of last follow-up for patients without progression and alive at the end of the study.&#xD;
PFS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two-sided log-rank test.</description>
          <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D, 128 instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134 instead of 138 (4 lost pts.).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.4" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.3" upper_limit="3.7"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.4" upper_limit="3.9"/>
                    <measurement group_id="O4" value="2.5" lower_limit="2.3" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall Response Rate (ORR) included Complete Response (CR) and Partial Response (PR).&#xD;
Complete Response (CR) was defined as disappearance of all symptoms and signs of all measurable disease, lasting for at least four weeks, without appearance of new lesions.&#xD;
Partial Response (PR) was defined as a &gt; 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, lasting for at least four weeks, without appearance of new lesions or enlargement of existing lesions.</description>
        <time_frame>18 weeks from start of therapy</time_frame>
        <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D 128, instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134, instead of 138 (4 lost pts.).</population>
        <group_list>
          <group group_id="O1">
            <title>Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine/Interferon + Dacarbazine</title>
            <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
          <group group_id="O3">
            <title>Fotemustine/Dacarbazine/Interferon+Dacarbazine/Interferon</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
          </group>
          <group group_id="O4">
            <title>Fotemustine/Dacarbazine + Dacarbazine</title>
            <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall Response Rate (ORR) included Complete Response (CR) and Partial Response (PR).&#xD;
Complete Response (CR) was defined as disappearance of all symptoms and signs of all measurable disease, lasting for at least four weeks, without appearance of new lesions.&#xD;
Partial Response (PR) was defined as a &gt; 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, lasting for at least four weeks, without appearance of new lesions or enlargement of existing lesions.</description>
          <population>Nine patients were lost to follow-up immediately after randomization and, in particular, for FDI + FD 132, instead of 136 randomized (4 lost pts.), for DI + D 128, instead of 133 (5 lost pts.), for FD1 + DI 126, instead of 131 (5 lost pts.), 134, instead of 138 (4 lost pts.).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Toxicity</title>
        <description>worst grade CTC toxicity, for each cycle and overall, will be reported for each treatment arm</description>
        <time_frame>at end of each 3 week cycle of therapy up to the discontinuation</time_frame>
        <population>It wasn't possible to assess the treatment related toxicity for all the patients included in the study because for some of them, no data were collected.&#xD;
It's difficult to indicate the exact number of participants affected by the worst grade CTC toxicity because the same patient could be affected by one or more side effects.</population>
        <group_list>
          <group group_id="O1">
            <title>Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine/Interferon + Dacarbazine</title>
            <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
          <group group_id="O3">
            <title>Fotemustine/Dacarbazine/Interferon+Dacarbazine/Interferon</title>
            <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week&#xD;
single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
          </group>
          <group group_id="O4">
            <title>Fotemustine/Dacarbazine + Dacarbazine</title>
            <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Toxicity</title>
          <description>worst grade CTC toxicity, for each cycle and overall, will be reported for each treatment arm</description>
          <population>It wasn't possible to assess the treatment related toxicity for all the patients included in the study because for some of them, no data were collected.&#xD;
It's difficult to indicate the exact number of participants affected by the worst grade CTC toxicity because the same patient could be affected by one or more side effects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>A1 - Combination Chemotherapy Without Interferon</title>
          <description>combination chemotherapy without interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle</description>
        </group>
        <group group_id="E2">
          <title>A2 - Combination Chemotherapy With Interferon</title>
          <description>combination chemotherapy with interferon&#xD;
Fotemustine: 100 mg / m2 IV on day 1 repeated on a 3 week cycle&#xD;
Dacarbazine: 900 mg / m2 IV on day 2 repeated on a 3 week cycle&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
        <group group_id="E3">
          <title>B1 - Single Agent Dacarbazine Without Interferon</title>
          <description>single agent dacarbazine without interferon&#xD;
Dacarbazine: 900 mg/m2 IV on day 1 repeated on a three-week cycle</description>
        </group>
        <group group_id="E4">
          <title>B2 - Single Agent Dacarbazine Plus Interferon</title>
          <description>single agent dacarbazine plus interferon&#xD;
Dacarbazine: 900 mg / m2 every 3 weeks&#xD;
Interferon Alfa-2b: α2b 5 MUI three times per week</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" events="67" subjects_affected="27" subjects_at_risk="67"/>
                <counts group_id="E3" events="72" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E4" events="52" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="62" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E2" events="67" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E3" events="72" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="52" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="67" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E3" events="72" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="52" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paolo A Ascierto, M.D., Ph.D</name_or_title>
      <organization>NCI Naples</organization>
      <phone>+39 081 5903431</phone>
      <email>p.ascierto@istitutotumori.na.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

